Half-Year 2022 Financial and Clinical Trials Update
gRED immunology and ophthalmology development programs
Molecule
efmarodocokin alfa
(IL-22Fc, RG7880)
Indication
aGVHD
Phase # of patients
Status
Immunology
lb
18
FPI Q4 2020
Roche
CT Identifier
NCT04539470
FPI Q1 2020
Inflammatory bowel disease
|
68
NME (RG6287, GDC-8264)
Recruitment completed Q3 2021
EUDRACT201
9-002613-19
Inflammatory diseases
16
FPI Q4 2021
NME (RG6315, MTBT1466A)
Immunologic disorders
~24
FPI Q3 2020
astegolimab (Anti-ST2,
Chronic obstructive pulmonary
llb
930
FPI Q4 2021
NCT05037929
(RG6149, AMG 282, MSTT1041A)1
disease
NME (RG6341, GDC-6599)
Asthma
la/lb
84
FPI Q4 2021
Ophthalmology
galegenimab
Geographic atrophy
||
360
FPI Q2 2019
(HtrA1, RG6147)
NME (RG6312)
NME (RG6351)
Geographic atrophy
la
63
FPI Q4 2020
Retinal disease
|
42-78
FPI Q2 2022
Partner: 1Amgen
NCT03972709
(GALLEGO)
NCT04615325
158View entire presentation